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tite. One day prior to admission, the patient saw her primary
physician, who noted that she was moderately hypertensive,
with a blood pressure of 140/80 mm Hg as compared to a blood
pressure of 110/70 mm Hg at six weeks of gestation. He also
noted 31 proteinuria on dipstick. A 24-hour urine collection
contained 9 g of protein; the creatinine clearance was 102 mL/
min. Serum creatinine had risen to 1.6 mg/dL from 1.0 mg/dL
earlier in the pregnancy. ANA was positive at 1:320. Following
this visit, the patient developed vaginal bleeding and presented
the next day to the emergency department at the Brigham and
Women’s Hospital.
In the emergency room, the patient had no active vaginal
bleeding. The medical history was noteworthy for a diagnosis
of rheumatoid arthritis, hypothyroidism with a multinodular
goiter, and mitral valve prolapse. She was taking levothyroxine
sodium (Synthroid), 0.05 mg daily. She reported having oneCASE PRESENTATION
sister with an unspecified autoimmune disorder.A 32-year-old woman was gravida 2, para 0, and had had
Physical examination revealed a patient comfortable at rest.one spontaneous abortion. When she was 12 weeks pregnant,
Her blood pressure was 138/78 mm Hg and she was afebrile.she presented to the emergency department at the Brigham
Her weight was 182 pounds. Head and neck examination wasand Women’s Hospital with new-onset nephrotic syndrome
remarkable for facial edema. No lymphadenopathy was appar-and systemic lupus erythematosus. Seven years earlier, she
ent, and the joints and skin were normal. Cardiac examinationhad had swelling in the small joints of her upper and lower
was normal. Lung examination revealed decreased breathextremities. At that time she was told that she had rheumatoid
sounds one-half way up with dullness to percussion in the rightarthritis. Hydroxychloroquine sulfate (Plaquenil) relieved her
hemithorax. The abdominal examination revealed distensionsymptoms. After five years of treatment, the patient discontinued
consistent with ascites. The uterus was not palpable. The ex-taking the Plaquenil, as she was concerned about becoming
tremities showed 21 pitting edema bilaterally. Her calves werepregnant. She did very well after the medication was stopped.
not tender. A pelvic examination did not reveal bleeding.Approximately two years before this admission, she became
The O2 saturation was 98% while breathing room air. Apregnant. Other than a positive rapid plasma reagin, all antena-
chest radiograph revealed a right pleural effusion and righttal tests were in the normal range. At approximately eight
chest wall subcutaneous emphysema. An ultrasound studyweeks gestation, the patient had a spontaneous abortion. She
demonstrated an intrauterine pregnancy at 12.5 weeks, ascites,underwent a dilatation and curettage because of hemorrhage
and a right pleural effusion. A urinalysis showed a specificand was diagnosed with a septate uterus. The septum was hyster-
gravity of 1.025; pH, 6.0; 31 protein; and 31 blood; the restoscopically resected one year prior to the current admission.
of the parameters were negative. Sediment examinationThe patient had been well until approximately eight weeks
showed 25 to 30 white blood cells/high-power field and too-into her current pregnancy, when she developed facial, hand,
numerous-to-count red blood cells/high-power field with 5 toand leg edema. The edema gradually worsened, with a 12 pound
7 coarse granular/degenerating cellular casts. The blood ureaweight gain over the next four weeks. She also noted increasing
nitrogen was 35 mg/dL and the serum creatinine was 1.6 mg/dL.shortness of breath, abdominal distension, and decreased appe-
Electrolytes were in the normal range. A complete blood count
showed a hematocrit of 25.8%, white cell count of 1536/mm3
(normal, 4000–10,000/mm3), and platelet count of 128,000/mm3The Nephrology Forum is funded in part by grants from Amgen,
(normal, 150,000–450,000/mm3). Liver function tests were nor-Incorporated; Merck & Co. Incorporated; AstraZeneca LP; Dialysis
mal. Her total protein was 3.3 g/dL (normal, 6.0 to 8.0 g/dL);Clinic, Incorporated; and R & D Laboratories.
albumin, 1.4 g/dL (normal, 3.7 to 5.4 g/dL); calcium, 6.8 mg/dL
Key words: systemic lupus erythematosus, human reproduction, im- (normal, 8.8 to 10.5 mg/dL); phosphorus, 4.6 mg/dL (normal,
mune system and pregnancy, maternal immune response, fetal anti- 2.4 to 5.0 mg/dL); magnesium, 2.7 mg/dL (normal, 1.8 to 6.4
gens. mg/dL); and uric acid, 6.5 mg/dL. Serum cholesterol was 259
mg/dL (normal, 140 to 240 mg/dL); the triglyceride level wasÓ 2000 by the International Society of Nephrology
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379 mg/dL (normal, 35 to 135 mg/dL). Serologic tests showed sone, 60 mg/day. Her therapeutic regimen comprised six monthly
pulses of intravenous cyclophosphamide followed by four pulsesa C3 of 84 mg/dL (normal, 88 to 201 mg/dL); C4, 21 mg/dL
(normal, 12 to 36 mg/dL); CH50, 128 U/mL (normal, 150 to of cyclophosphamide, one every three months. Her cyclophos-
phamide treatment has since been discontinued (cumulative250 U/mL); and a Clq of 27 mg/dL (normal, 8 to 12 mg/dL). The
anti-double stranded (DS) DNA antibody was 78 IU (normal, 0 dose, 10 g over 18 months). Her prednisone dose has been
tapered gradually.to 25 IU); anti-sm antibody, 4 EU/mL (normal, 0 to 20 EU/
mL); anti-Ro 4 EU/mL (normal, 0 to 20 Em/mL); ANA, 1:640; Over the past five years, she has experienced no further
renal or extrarenal manifestations of lupus. Her renal functionand a negative ANCA. Her anti-cardiolipin antibody titer was
,22 GPL units (normal, ,15). The lupus anticoagulant screen has remained stable. One year following her acute illness, the
serum creatinine was 0.8 mg/dL. An iothalamate test of glomer-was negative.
A provisional diagnosis of lupus nephritis with nephrotic ular filtration rate showed 100 mL/min/1.73 m2, and a 24-hour
urine collection contained 423 mg protein. Four years followingsyndrome was made. The patient was treated with prednisone,
60 mg/day, and furosemide, 40 mg/day. A renal biopsy was her acute illness, the serum creatinine remained at 0.8 mg/dL,
with a creatinine clearance of 141 mL/min and a 24-hour urinedeferred because of the pregnancy. Over the next five days,
the patient had further vaginal bleeding, and her hematocrit protein excretion of 233 mg. At last follow-up, approximately
five years following her acute illness, her serum creatininefell to a nadir of 20%. The serum creatinine peaked at 1.8
mg/dL, and a 24-hour urine collection revealed 12 g of protein. was 0.9 mg/dL with a creatinine clearance of 120 mL/min and
undetectable amounts of protein in a 24-hour urine collection.After much discussion, the patient elected to terminate the
pregnancy on the seventh day following admission. Subse-
quently, the ascites and peripheral edema progressively im-
proved. Prednisone was continued at the same dosage and she DISCUSSION
was discharged from the hospital. Dr. Ajay K. Singh (Clinical Director, Renal Division,A percutaneous renal biopsy was performed approximately
Brigham and Women’s Hospital; and Associate Professor10 days following termination of the pregnancy. The biopsy
of Medicine, Harvard Medical School, Boston, Massa-consisted of two cores of renal tissue containing a total of 21
glomeruli. Five glomeruli showed periglomerular cellular or chusetts, USA): Systemic lupus erythematosus (SLE) and
fibrocellular crescents. All glomeruli were remarkable for dif- the anti-phospholipid antibody syndrome (APS) are au-
fuse endocapillary cell proliferation. Few open loops were pres- toimmune syndromes that occur most commonly inent. Numerous “wire-loop” lesions were present and frequent
women during their reproductive years. Forty years ago,capillary loops revealed thickened walls with double contours.
approximately one of every 1660 pregnancies involvedOccasional polymorphonuclear leukocytes were identified
within the glomerular capillary tufts, and rare areas showed a mother with SLE. The frequency of pregnancy in lupus
evidence of cellular damage with karyorrhectic debris. Most patients is now severalfold higher for a variety of reasons,
glomeruli showed a segmental increase in mesangial matrix including the emergence of immunosuppressive agentsand cells. The interstitium showed a few foci of mononuclear
to better manage lupus, the marked improvement incell infiltration. There was focal mild interstitial fibrosis as well
obstetric care, and the realization among patients andas focal mild tubular atrophy; however, most tubules were
arranged in a normal back-to-back configuration with full epi- physicians that pregnancy is not contraindicated in SLE.
thelium. Mild thickening of arteries and arterioles was appar- Today’s case presentation highlights a number of ques-
ent. The activity index was 16, with a maximal score of 24. The
tions that will be the focus of my discussion. First, whatchronicity index was 3, with a maximal score of 12. The sections
is the effect of pregnancy on the immune system andwere examined for reaction with antibodies against IgG, IgA,
IgM, C3, albumin, fibrinogen, and kappa and lambda light how is it of relevance to patients with SLE? Second, how
chains. Twelve glomeruli were present on the examined sec- does pregnancy affect SLE activity? In particular, what
tions. Diffuse granular reactivity was identified within glomeru- is the lupus flare rate during pregnancy, and does preg-
lar tufts with antisera to IgG (31/41), IgA (2–31/41), IgM
nancy exacerbate SLE activity? Further, does the clinical(11/41), and kappa/lambda light chains (trace to 11/41).
severity of lupus at onset of pregnancy predict the proba-Granular C3 (21/41) was identified within glomeruli in a dif-
fuse segmental manner. The reactivity was found along glomer- bility of further worsening of disease during that preg-
ular capillary loops and most likely in mesangial areas. Small, nancy? Third, what is the effect of SLE on pregnancy?
segmental, confluent areas of fibrin/fibrinogen reactivity (31/ In particular, how does SLE affect maternal and fetal41) were identified within some glomeruli. Linear albumin
outcome? Finally, what is the role of the anti-phospho-(trace) was identified along all basement membranes. Two
lipid antibody syndrome on pregnancy and fetal out-glomeruli were examined by electron microscopy. Numerous
subendothelial electron-dense deposits were identified. Rare come, and how should APS be managed?
subepithelial and more frequent mesangial deposits also were
found. No specific structures were identified within the depos- Immunologic adaptations in pregnancy
its. Visceral epithelial cells showed obliteration of foot pro-
Among the many physiologic adaptations that occurcesses. Diffuse mesangial cell proliferation also was evident.
during pregnancy, the adaptation of the immune systemBased on the renal biopsy, a diagnosis of WHO class-IV
diffuse proliferative lupus nephritis was made. The patient was in the mother to a semi-allogeneic fetus is, perhaps, the
counseled about the potential effects of cyclophosphamide on least well understood. This immunologic balancing act
future fertility, and she elected to undergo further treatment. allows the mother to avoid mounting a vigorous immuneOne month following the onset of her nephritic illness, she
response to the presence of paternal major histocompati-was given pulse intravenous cyclophosphamide therapy (1 g
intravenously each month) while continuing to take predni- bility (MHC) antigens, and yet allows her to maintain
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normal immune competence for defense against micro- in the non-pregnant state. The effects of these com-
pounds on the immune system are complex. As I alludedorganisms. Although there are no significant differences
in the absolute numbers of T- and B-lymphocytes and to earlier, progesterone suppresses lymphocyte prolifer-
ation by modulating the Th1/Th2 cytokine balance [re-NK cell numbers, strong evidence demonstrates a switch
from a Th1 to a Th2 response in pregnancy [1], as well viewed in 9] through the release by lymphocytes of PIBF
[8]. Progesterone-induced blocking factor then mediatesas several potentially important functional adaptations.
Comparisons of the mixed-lymphocyte reactions (MLR) the immunomodulatory effects of progesterone through
the induction of Th2-type cytokines by activated lympho-of normal pregnant women and their non-pregnant,
HLA-identical sisters indicate that, despite the presence cytes. In addition, progesterone-induced lymphocytes
produce soluble factors that favor the synthesis of prosta-of fetal (paternal) HLA antigens, maternal MLR are
neither stimulated nor suppressed [2, 3]. Studies also glandin E, which in turn might suppress IL-2 production
from both NK cells and T-lymphocytes. Estrogens, onreport either normal or reduced NK cell cytolytic activity
as well as suppression of lymphocyte proliferation. These the other hand, stimulate an increase in maternal hepatic
protein synthesis, which raises the concentration of aalterations appear to be modulated by a 34 kD protein
produced by lymphocytes named the progesterone-in- variety of serum proteins. Although estrogen is stimula-
tory for T-cell responses and autoantibody production,duced blocking factor (PIBF), which both influences lym-
phocyte and NK function and modulates the Th1 to Th2 the fact that neither T-cell function nor immunoglobulin
production increases dramatically during pregnancy sug-switch [4, 5]. Because production of immunoglobulin and
circulating levels of IgG, IgM, and IgA also are normal, gests counterbalancing influences [10]. These counter-
balancing immune suppressive factors include progester-B-cell function is likely intact. The mother does produce
antibodies against some fetal (paternal) HLA antigens one, a-fetoprotein, a pregnancy-specific b1-glycoprotein,
pregnancy-associated a2-macroglobulin, and human cho-beginning at around eight weeks of gestation [6]; how-
ever, these autoantibodies are non-cytotoxic and regu- rionic gonadotropin [10]. Whether progesterone-in-
duced Th2 activity modulates lupus during pregnancy islated by an idiotypic network [7] that facilitates control
of the immune response. Thus, pregnancy manifests se- still open to debate. Studies of pregnant lupus patients
matched with non-pregnant controls suggest that preg-lective functional changes in maternal immune responses
that include a switch from Th1 to Th2 and a dampening nancy does not exacerbate clinical lupus activity [11, 12],
but this remains a controversial issue. On the other hand,of the response to fetal (paternal) HLA antigens.
The maternal immune response during pregnancy has there appears to be agreement that lupus that is active
at the onset of pregnancy is activated further duringbeen investigated with respect to both rheumatoid arthri-
tis and SLE. Rheumatoid arthritis tends to remit rather pregnancy, as evidenced by either clinical activation of
disease, worsening of serologies, or both. One explana-than flare in pregnancy [8, 9]. This salutary effect of
pregnancy on the disease activity appears to be modu- tion for this difference could be that lymphocytes, after
being activated during a pre-pregnancy exacerbation oflated by a maternal-fetal disparity in HLA-DR and DQ
antigens [8] as well as a switch from Th1 to Th2 T-cell disease, become more responsive to Th2 cytokines dur-
ing pregnancy. According to this hypothesis, pregnancyresponses. Unlike investigations into rheumatoid arthri-
tis, studies in murine lupus models suggest that a switch does not induce flaring of lupus, but already active lupus
can worsen during pregnancy because of the Th2 biasto Th2 responses favors further activation of the immune
response in SLE. Thus, the predominance of Th2 re- in immune responses.
The mechanisms underlying maternal tolerance to thesponses in pregnancy might explain why lupus tends to
flare during pregnancy. semi-allogeneic fetus at the feto-placental interface also
are beginning to be understood. Rejection of the tropho-Immunologic adaptations during pregnancy are influ-
enced by major endocrine changes, which might be rele- blast is prevented through the regulated expression of
major HLA antigens by placental trophoblast cells [13].vant to pregnancy-associated lupus activity. Progester-
one, estrogen, and androgen levels increase markedly Transcription and translation of the highly polymorphic
class-I HLA-A, -B, and -C genes, whose products play aduring pregnancy. These changes are at first orchestrated
by the corpus luteum, which makes progesterone during critical role in graft rejection, are blocked in trophoblast
cells. In place of HLA-A, -B, and -C, trophoblast cellsthe initial six to eight weeks of gestation. Subsequently,
progesterone is synthesized and secreted by the placenta. express HLA-G, a nonclassic, nonpolymorphic major
histocompatibility complex class-I molecule, which is ex-In addition to progesterone, the feto-placental unit is a
major source of production of estrogen via a pathway pressed in a restricted fashion on trophoblasts. Expres-
sion of HLA-G also appears to inhibit NK cell activity,involving the fetal adrenal gland and the compounds
dehydroepiandrosterone and dehydroepiandrosterone as well as T-cell function. The role of HLA-G has been
discussed elsewhere in detail [14]. While trophoblast cellssulfate. Maternal concentrations of progesterone and es-
trogen increase to four to eight times the level observed do not express class-II HLA-D antigens, they do express
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Fas ligand, thereby conferring immune privilege. Fur- lupus flare was not defined at all [20]. In contrast, in
several other studies (in which the flare rate ranged fromthermore, trophoblasts express the complement regula-
tory proteins CD46, CD55, and CD59 [15]. A number 37.5% to 54.0%), clinical criteria defined a lupus flare
[21–23]. Retrospective studies also have been dogged byof cytokine responses also appear to be important in
implantation [16]. Interferon-g, which usually increases small numbers of patients (as few as eight patients in
one study [22]), non-random selection of subjects, useHLA expression, appears to have no effect on tropho-
blast cells in situ. On the other hand, increased expression of patients with more severe underlying disease, and
either the lack of a control group or the use of patients asof cytokines, including IL-1, TNF-a, IFN-g, GM-CSF, and
CSF-1, influence blastocyst attachment, trophoblast out- their own controls. In studies in which carefully matched
non-pregnant patients were used as controls, no excessgrowth, implantation, proliferation of trophoblast cell
lines, and placental function. Uterine decidual and pla- flare rate was noted with pregnancy [11, 12], whereas
in studies in which patients themselves functioned ascental cells also bias the Th response towards Th2. Fi-
nally, the placental barrier restricts the traffic of cytotoxic controls, an excess flare rate was documented [21, 24].
The main problem with self-controls is that signs of activecells to the fetus, and cytotoxic antibodies are removed
by the placenta before they reach the fetal circulation. disease can diminish over time in patients with SLE.
Furthermore, the use of historical controls rather thanThe balancing of immunologic and endocrine factors
ensures the success of pregnancy. In essence, there are concurrent controls or the use of “published flare rates
in other populations” has obvious limitations. Studiestwo battlegrounds: systemic, where tolerance of the ma-
ternal immune system to fetal (paternal) antigens in the that report a relatively low rate of lupus flare in the
control population also are not necessarily representa-circulation occurs, and local, at the feto-placental inter-
face. Some evidence indicates that the level of disparity tive of the observed rate in other centers, and compari-
sons among studies might not be valid. In some studies,between maternal and fetal antigens (of the major HLA
antigens) in pregnancy influences immune respon- the level of disease activity at the onset of pregnancy
has been poorly documented. Single-center studies aresiveness, at least in patients with rheumatoid arthritis.
Whether this finding is applicable to SLE remains to be also open to biases. For example, studies from a high-
risk obstetric center can comprise patients who have aseen. Studies from murine models suggest that the time
of greatest likelihood for activation of lupus is the “child- history of more severe lupus—and therefore more likely
to flare—compared with those from less-specialized cen-bearing” period (rather than pregnancy itself) because
the immune stimulatory effect of estrogen is unopposed ters where the patients might have less-severe disease.
Prospective controlled studies unfortunately have alsoat this age. In the NZB/W murine model of SLE, reduc-
tion in the estrogen stimulus or an increase in the andro- generated conflicting results. Lockshin et al reported that
the lupus flare rate is approximately 20% and found nogenic influence is associated with amelioration in disease
activity [17]. In addition, sporadic evidence links exoge- difference in the flare rate when pregnant lupus patients
are compared with matched non-pregnant lupus controlsnous estrogen therapy with the precipitation of a lupus
flare. This issue is reviewed elsewhere in greater detail [11]. In contrast, Petri and coworkers reported a flare
rate of approximately 60% and suggested that pregnancy[18]. However, as I said earlier, to the extent that autoim-
mune activity proximate to the onset of pregnancy (,6 exacerbates lupus activity [24, 25]. Several factors might
explain this large discrepancy between prospective stud-months) is associated with a greater flare rate during
pregnancy, it is likely that the level of autoimmune activ- ies from experienced centers. The most important factor,
as is the case with retrospective analyses, appears to beity at the onset of pregnancy influences subsequent dis-
ease activity during gestation. a lack of consensus on the definition of a lupus flare, even
in carefully designed, prospective studies. Worsening of
Effect of pregnancy on lupus activity disease activity along a continuum, worsening of one
aspect of lupus (for example, nephritis), or intensificationThe potential impact of pregnancy on lupus activity
has been debated for decades. Bridge and Foley con- of prednisone dosing all have been cited as “flares.” But
increased activity of a clinical abnormality or laboratorycluded in a 1954 article that “there is no constant effect
of pregnancy on this disease” [19]. A large number of dysfunction is not always attributable to lupus. For exam-
ple, worsening of proteinuria or hypertension could re-studies have since examined this issue, but no consensus
has emerged. The lupus flare rate, examined in numerous flect changes attributable to pregnancy itself rather than
to lupus. Facial and palmar erythema, thrombocyto-studies [11, 12, 20–24], ranges from approximately 20%
to 60% (Fig. 1). Retrospective studies invariably have penia, and effusions also are commonly a feature of a
normal pregnancy, but their presence could be misinter-noted an increased flare rate in pregnant women with
lupus. However, these studies have significant limita- preted as a flare.
Another factor that might explain a higher flare ratetions, including variable definitions of a lupus flare. For
example, in one study reporting a flare rate of 22%, is the quality of matching of pregnant patients with their
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Fig. 1. Frequency of a lupus flare (in percent-
age) for 11 retrospective and prospective stud-
ies spanning three decades. The rate ranges
from 20% to 60%. The citation number is
given in parentheses.
controls. In the Petri studies, differences in baseline char- remains controversial. Lockshin’s prospective data with
well-matched controls suggest not.acteristics such as age (older patients in the control
group), race (more African Americans in the control Several factors present prior to the onset of pregnancy
have been proposed as predictive of whether SLE willgroup), and the prednisone dose (higher in the non-
pregnant control group) also could explain the higher flare during pregnancy. These include presence of dis-
ease activity at the time of conception, duration of remis-flare rates among the pregnant lupus patients as com-
pared with controls [25]. Follow-up of control patients sion prior to the onset of pregnancy, and pattern of
SLE activity in multiple pregnancies. In a study of 79was also different, that is, less frequent in the control
group compared with the pregnant lupus patients. Fi- pregnancies in 36 patients, Estes and Larson suggested
35 years ago that the level of SLE activity at the timenally, inclusion of patients who developed SLE during
the index pregnancy could be considered controversial, of conception is critically important [26]. In patients with
active SLE, exacerbations of lupus during pregnancybecause, strictly defined, de novo onset of lupus does
not represent a flare of lupus per se; thus the association occurred more than twice as often as remissions, and
these exacerbations were most frequent in the post-par-of lupus and pregnancy could have occurred by chance.
Studies reporting the absence of an excess lupus flare tum period. More recent studies have not reported a
higher rate of lupus flares in the post-partum period,rate in pregnancy, on the other hand, also have been
criticized. In Lockshin’s study, lupus patients appeared however (Fig. 2) [21, 25, 27–29]. Estes and Larson also
suggested that nephritis appeared to worsen progres-to have mild disease—as evidenced by the relatively
small proportion of patients taking prednisone (,40%) sively during pregnancy. Several reports have confirmed
this observation [21, 30–32]. Using survey data, Hayslettand the incidence of flares among the non-pregnant lupus
controls—and the population might not have been repre- and Lynn found that if SLE had been in clinical remission
for at least six months prior to conception, 65% of thesentative of the general lupus population [11]. The ab-
sence of a significant difference in the frequency of flares patients had a sustained remission, and only 32% had
clinical evidence of a relapse. In contrast, active lupusin the study and control populations could simply reflect
a sample size inadequate to detect this anticipated effect. at the time of conception was associated with increased
or persistent lupus activity in 52% of patients [30]. ANevertheless, despite the limitations of the various stud-
ies, patients seek guidance about the likelihood of a flare more recent study from Bobrie et al produced similar
findings [32]. In the Bobrie study, lupus activity at con-during pregnancy. From my review, the best available
data suggest a 20% to 60% likelihood of a lupus flare, ception also correlated with more severe flares and in-
cluded progression to end-stage renal failure in somedepending on how one defines the severity of lupus in
the patient and the criteria for diagnosing activity of the patients. Zulman et al examined the factors that predict
SLE activity during pregnancy. They reported a clinicalunderlying disease at conception. Whether pregnancy is
in fact associated with a higher risk of a lupus flare flare in 10 of 16 patients who had active renal disease
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Fig. 2. Frequency of a lupus flare (in percent-
age) in the different phases of pregnancy and
the postpartum period. There appears to be
no consistent relationship between the phase
of pregnancy and lupus flare activity. Symbols
are: (j) Fraga et al [29]; ( ) Mintz et al [27];
(h) Petri et al [25]; ( ) Zulman et al [21];
( ) Carmona et al [28].
Fig. 3. Effect of disease activity on the subse-
quent rate of lupus flare. Remission at the
onset of pregnancy appears to be associated
with a lower flare rate than if SLE is active
at conception. Symbols are: (j) Hayslett et
al [30]; (h) Bobrie et al [32]; ( ) Tozman et
al [39]; ( ) Urowitz et al [31].
but in only one of 6 without active renal disease prior because these patients commonly manifest thrombocyto-
to pregnancy. None of the patients without renal disease penia. Complement levels sometimes are useful diagnos-
prior to pregnancy developed renal disease during preg- tically but generally lack specificity. Normal pregnancy is
nancy [21]. Although far from proven definitively, a rea- marked by an increase in complement levels, particularly
sonable body of evidence seems to support the contention C3, C4, and CH50 [34]. However, low or normal comple-
that conception during active lupus, particularly in patients ment levels can be difficult to interpret because some
with active lupus nephritis, should be avoided (Fig. 3). A uncomplicated lupus pregnancies also are accompanied
prudent rule of thumb based on the prevailing data is by low complement levels. To address problems with the
that SLE patients should wait at least six months after specificity of hypocomplementemia in diagnosing a lupus
remission of lupus activity before becoming pregnant. flare, investigators have measured both complement and
complement split product such as Ba, C3a, C4d, SC5b-
Effect of SLE on pregnancy and fetal survival 9 and utilized ratios of these measurements (for example,
a high CH50:Ba ratio). However, because assays measur-Systemic lupus erythematosus can influence pregnancy
in several ways: induction of a pre-eclampsia-like syn- ing complement split products are not widely available
in clinical practice, their value in managing a lupus preg-drome, worsening of renal disease, and an increased risk
of fetal morbidity and mortality. A lupus flare comprising nancy is limited.
Numerous reports have documented a high rate ofthrombocytopenia, hypertension, azotemia, and sodium
avidity is difficult to distinguish from pre-eclampsia adverse outcomes in pregnant patients with lupus [12,
23, 27, 30, 35–37]. These poor outcomes include a high[21, 33]. This is particularly true when pregnant lupus
patients have circulating anti-phospholipid antibodies, rate of fetal loss, a high frequency of late miscarriages
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and premature deliveries, and intrauterine growth retar- various histologic lesions are open to non-random selec-
tion bias. Notwithstanding these legitimate concerns,dation. Studies on fetal outcome are difficult to compare
because they span a time frame that has witnessed major Tozman et al reported that 11 of 18 patients had evidence
of renal disease either clinically or on renal biopsy; 2 ofimprovements in obstetric care, the relatively recent rec-
ognition of the role of anti-phospholipid antibody syn- the 11 had nephrotic syndrome [39]. The most common
lesion (in 4 of 11 patients) was WHO class-II lupus ne-drome and the neonatal lupus syndrome in modulating
fetal wastage, and the introduction of several therapeutic phritis. Unfortunately, the effect of pregnancy on either
the clinical or laboratory parameters of renal disease wasmodalities to improve outcomes. Furthermore, studies
have utilized different criteria in defining outcomes. For not documented. Zulman et al retrospectively analyzed
their data and reported that of 24 pregnant patients,example, it is unclear whether fetal loss included late
fetal deaths in utero, stillbirths, or deaths soon after only 2 developed nephrotic syndrome during pregnancy.
Notably, lupus flares occurred most commonly in pa-birth. If one excludes studies prior to 1980, the rate of
live births in pregnant lupus patients is 74% (fetal loss tients who had renal involvement [21]. In a study by
Rubbert and coworkers of 21 pregnancies in 19 lupusrate of 26%). This rate is consistent with data from a
prospective study from France, which reported a live patients, 4 patients had renal involvement [40]. These
patients had a worsening of proteinuria, from 1.3 to 3.7birth rate of 76% [35]. In contrast, in another prospective
study, this one originating in China, a significantly lower g/24 hr to a range of 6 to 10 g/24 hr. All the patients
had complicated obstetric outcomes, ranging from pre-live birth rate (58%) suggested a geographic variation
perhaps related to differences in available technology eclampsia (2 of 4 patients), spontaneous abortion (one
patient), and preterm delivery (one patient).[36]. The rate of spontaneous abortions is 18%, higher
in patients with SLE than the rate in the general popula-
Neonatal lupus syndrometion but generally lower than figures pre-dating 1980.
The main risk factors linked to fetal loss include preterm The neonatal lupus syndrome is the most dramatic
immunologic example of the maternal immune systemdelivery, the presence of the neonatal lupus syndrome,
active disease prior to or early in pregnancy, and the transferring an autoimmune disease to the fetus. Only a
small fraction of mothers with lupus or other rheumaticpresence of abnormal renal function, proteinuria, or anti-
phospholipid antibodies in the patient. However, the diseases deliver infants that develop neonatal lupus ery-
thematosus (NLE) [41]. However, mothers who haveliterature lacks any comprehensive analysis that weighs
the importance of these risk factors in determining fetal circulating anti-SSB/La and SSA/Ro antibodies confer
a high risk of NLE on the fetus [41]. Initially describedoutcome.
Preterm delivery is a major influence on fetal morbid- by McCuistion and Schock in 1954 [42], NLE is the result
of transplacental transfer of pathogenic anti-La/SSB andity in normal patients and in patients with lupus. The
preterm delivery rate in lupus pregnancies varies extraor- Ro/SSA autoantibodies from the mother to the fetus.
The syndrome comprises transient cutaneous lupus ery-dinarily widely among different studies, ranging from
13% to 74%. One potentially important factor that might thematosus that presents as a generalized photosensitive
rash, hematologic abnormalities including thrombocyto-explain this apparent discrepancy is the varying defini-
tions of preterm delivery. In a study by Zulman et al, penia and anemia, giant cell hepatitis with severe chole-
stasis, and isolated complete heart block [43]. Rarely,the reported rate was 13% [21]; however, Johnson et al
reported a rate of 50% [38] and Imbasciati and col- nephrotic syndrome or a myasthenia-like presentation
has been reported [44, 45]. Complete heart block is usu-leagues reported a rate of 74% [37]. Causes of preterm
delivery in the Johnson study included premature rup- ally diagnosed in the second trimester, when fetal brady-
cardia is detected. Other cardiac manifestations includeture of membranes (39.0%), pre-eclampsia or preg-
nancy-induced hypertension (32.4%), and spontaneous myocarditis, congestive heart failure, and a pericardial
effusion; cardiac pathology is discussed in greater detailpremature labor (11.8%) [37]. The mechanisms underly-
ing the high rate of premature rupture of membranes in elsewhere [46]. Neonatal lupus erythematosus can occur
as a part of, or precede the development of, the maternallupus pregnancies remain poorly understood. Indeed, in
a relatively recent study, premature rupture of mem- autoimmune disease, most frequently SLE. In a study
by Buyon and colleagues of children with congenital heartbranes did not seem to correlate with prednisone use,
disease activity, or lupus serologic parameters [37]. block, 34% of the mothers had SLE, 16% had Sjo¨gren’s
syndrome, 22% had undifferentiated autoimmune dis-How does pregnancy affect the severity of lupus ne-
phritis? Retrospective and prospective studies have re- ease, and 28% had no overt autoimmune disease [47].
The association between NLE and anti-SSA/Ro and/orported that patients with pre-existing renal disease have
worse outcomes in terms of preterm delivery, incidence anti-SSB/La in affected mothers and infants was first
described in 1983 [48]. Since then, several groups haveof pre-eclampsia, and worsening of proteinuria. The inci-
dence of clinical renal syndromes and the frequency of examined the pathogenetic, structural, and genetic origins
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of the putative pathogenic autoantibodies. Several lines ponent of anti-SSA/Ro). If the fetus has an abnormal
echocardiogram, dexamethasone (because it is not me-of evidence support a pathogenetic role for anti-SSA/Ro
and anti-SSB/La antibodies in NLE. These include ob- tabolized by the placenta and is available in an active
form to the fetus) and plasmapheresis have been sug-servations demonstrating the reactivity of maternal im-
munoglobulin to fetal heart tissue, the correlation be- gested [54].
tween maternal antibody titer and clinical illness in the
Anti-phospholipid antibody syndromechild, and experiments using rabbit hearts perfused with
during pregnancyanti-SSA/Ro and anti-SSB/La sera [reviewed in 49]. There
also appears to be a close correlation between the pres- Pregnancy-associated complications of the antiphos-
pholipid antibody syndrome affect both the mother andence of the anti-SSA/Ro antibodies and the presence of
congenital heart block [43], but the precise mechanisms the fetus. These include fetal death (which can occur
early or late), intrauterine growth retardation, prematureby which autoantibodies interfere with conduction in the
fetal myocyte or Purkinje cell remain obscure. delivery, and dysmaturity. Consensus exists that the pres-
ence of antiphospholipid antibodies (APAs) in pregnantAutoantibodies to SSA/Ro recognized a ribonucleo-
protein complex composed of small single-stranded women is associated with a high risk of repeated abor-
tions before the 20th week; the frequency ranges fromRNAs and one or more peptides [reviewed in 49]. Two
molecular forms of this complex are prominently in- 53% in a study by Branch et al [55] to 77% in a study
by Prentice et al [56]. There is also a risk of unexpectedvolved, a 52 kD peptide and a 60 D form. The Ro com-
plex has a diverse tissue and cell distribution, including intrauterine deaths in the second and third trimester; the
frequency ranges from 22% in the Prentice study [56]expression in erythrocytes and platelets. Its function re-
mains unknown, although it might participate in RNA to 46% in the Branch study [55]. In addition, the mother
can suffer from venous and/or arterial thrombosis; throm-transcription processes. The immune response to the
SSA/Ro antigen is heterogeneous. Anti-SSA/Ro-positive bocytopenia; pregnancy-induced hypertension; chorea;
multi-system organ failure, including renal, hepatic, andsera might contain antibodies recognizing either a 60- or
a 52 kD polypeptide component of the SSA/Ro particle. cardiac failure; and post-natal depression.
Although initially the APS was considered wholly aAntibodies to the 52 kD SSA/Ro protein have at least
two antigenic determinants, an “immunodominant” de- part of the SLE syndrome, it has become increasingly
evident that it can occur as a primary syndrome. Theterminant, and a second region recognized by a more
“restricted” subset of anti-52 kD SSA/Ro Abs [50]. The primary antiphospholipid antibody syndrome (PAPS),
described nearly two decades ago by Graham Hughes,60 kD protein has a molecular partner identified recently
as a novel 75 kD protein (pp75), which localizes predomi- is termed Hughes’ syndrome in his honor [57]. Primary
and secondary forms of APS have similar clinical profiles,nantly in the cytoplasm [51]. The heterogeneity of the
anti-SSA/Ro response and its relationship with underly- with the exception of lower C4, autoimmune hemolytic
anemia, endocardial valve disease, and neutropenia ining rheumatic disease have been examined. The major
responses are anti-52 kD antibodies in primary Sjo¨gren’s secondary APS [58]. Both forms are associated with
thrombosis and an increased risk of fetal wastage [58],syndrome, both anti-52 and anti-60 kD antibodies in
SLE, and anti-60 kD antibodies in rheumatoid arthritis although the frequency of fetal loss appears to be lower
in patients with primary APS than with SLE-associatedand other connective tissue diseases [52]. There is no
specific immunoglobulin subclass distribution of anti-48 secondary APS.
Antiphospholipid antibodies comprise a family of im-kD SSB/La and anti-52 and -60 kD SSA/Ro antibodies
in the maternal and neonatal circulation in affected munoglobulins whose specificity has been defined by in-
vitro assays. Initially the antigen was thought to be an-mothers and infants with NLE [53].
The management of NLE involves several strategies, ionic phospholipids. However, data over the past several
years indicate that these antibodies have variable speci-including aggressive preventive protocols, screening us-
ing two-dimensional and M-mode echocardiography, ficities. Antigenic moieties include b2-glycoprotein I, hu-
man prothrombin, placental anticoagulant protein (PAP),possible prenatal treatment with steroids, and early de-
livery. Maternal immunosuppression with steroids and thrombomodulin, tissue factor, and phospholipase A2.
Broadly, APAs can be regarded as a family of antibodiesplasmapheresis also were used with success in the 1970s
and 1980s. Buyon and her group recommend that all that, on the basis of in vitro assays, can be categorized
into three groups, lupus anticoagulant (LA), anticardio-mothers with anti-SSB/La or anti-SSA/Ro, particularly
with the 52 kD form, undergo serial fetal echocardiogra- lipin antibodies, and reagin antibodies. Since the original
description of LA in 1952 by Conley and Hartmann, thephy by an experienced pediatric cardiologist at 16, 18,
22, and 24 weeks of gestation [54]. They further suggest presence of LA in the serum has been correlated with
venous and arterial thromboembolism. Lupus anticoagu-consideration of prenatal prophylactic steroids in high-
risk patients (for example, mothers with the 52 kD com- lant interferes with one or more of the in-vitro phospho-
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lipid-dependent coagulation assays, such as the APTT, ginning to be understood. Evidence that Th1 cytokines
suppress manifestations of APS in animal models raisesprothrombin time, or dilute viper venom time (dRVVT).
Anticardiolipin antibodies currently are measured in ei- the possibility that a Th1-to-Th2 switch during pregnancy
makes mothers more vulnerable to APS [63]. Fetal lossther a solid-phase ELISA or a radioimmunoassay and
are directed predominantly against the b2-glyoprotein I appears to be the consequence of thrombosis of the utero-
placental vasculature as well as of placental infarctionmoiety, which is a physiologic anticoagulant. The b2-
GPI appears to inhibit the contact phase of coagulation [reviewed in 64]. Antiphospholipid antibodies might in-
duce a coagulant state by binding to antigens such asand impedes the prothrombinase complex (factor Xa,
factor Va, calcium ions, phospholipid, and prothrombin). phosphatidylserine, thrombomodulin, and heparan pro-
teoglycan on endothelial cells and trophoblast cell sur-Reagin antibodies react with the VDRL reagent. The
VDRL reagent denotes a mixture of antigens, including faces [65]. Indeed, in vivo studies in a murine model
support a direct thrombogenic role for APAs [66]. Beta2-cardiolipin, cholesterol, and lecithin. In contrast to the
presence of other APAs, studies indicate that a false- GPI appears to function as a cofactor that facilitates
this crucial interaction. The resulting endothelial cellpositive VDRL test in pregnancy does not increase the
risk of fetal loss. Studies characterizing the antiphospho- activation is associated with cell surface expression of
E-selectin, vascular cell adhesion molecule (VCAM-1),lipid antibody response report much heterogeneity in
antibody specificities. Approximately one-third of pa- and intracellular adhesion molecule (ICAM-1), and leads
to monocyte adhesion, the first step in thrombosis. Al-tients with SLE have antibodies detected as lupus antico-
agulant, and 40% to 60% of patients have anticardiolipin though the precise mechanisms mediating endothelial
cell-platelet interaction have not been fully elucidated,antibodies. In light of the spectrum of specificities and
the growing evidence that combinations of antibodies of platelet binding to the endothelium appears to be the
next phase in thrombosis. Potential targets for APA onvarious isotypes and specificities correlate with specific
clinical presentations, it is likely that future clinical work- platelets include platelet activating factor, phosphatidyl-
serine, and platelet glycoprotein IIIa. Evidence thus sug-ups of patients with APS will require assays that measure
these different antibodies. gests that APAs cause platelet activation and aggrega-
tion. Other abnormalities in the clotting system mightThe most prevalent anti-phospholipid antibodies are
anti-b2-GPI antibodies. “Pathogenic” anti-phospholipid conspire to further induce activation of the coagulation
cascade. These include protein C and/or protein S defi-antibodies, that is, those associated with disease, initially
were perceived as being exclusively IgG in isotype [59]. ciency [66, 67]. The target organ for the thrombotic events
appears to be the spiral arteries of the placental bed.However, recent work suggests that IgA and IgM iso-
types also are associated with disease. Thus, anti-b2-GPI A role for annexin V in APA-associated pregnancy
loss has been suggested. Rand and Wu postulate thatantibodies of IgG, IgA, and IgM isotypes were present
in 84.8%, 59.3%, and 51.5% of patients with APS, and annexin V, which is expressed by placental and vascular
endothelium, plays a thromboregulatory role at the vas-the frequency and level of each isotype were significantly
higher in patients with APS [60]. A strong relationship cular-blood interface by shielding anionic phospholipids
from forming a complex with coagulation proteins inalso has been demonstrated between increased IgA anti-
b2-GPI antibody levels and a history of venous thrombo- the circulation [68]. Thrombosis in the antiphospholipid
syndrome is due to disruption of the annexin shield bysis, thrombocytopenia, cardiac valve disease, livedo retic-
ularis, and epilepsy. Likewise, IgG anti-b2-GPI antibod- antiphospholipid (and cofactor) antibodies, which results
in the increased exposure of thrombogenic phospholip-ies, usually in association with the LA, are associated
with the main features of APS. In contrast, antibodies ids. Several lines of evidence support this hypothesis. In a
murine model, APAs rather than anti-b2-GPI antibodiesof IgM isotype are related only to thrombocytopenia and
cardiac valve disease. African Americans appear to have per se appeared to be thrombogenic [69]. Annexin V
displaced coagulation factors from phospholipid surfacesa higher frequency of IgA b2-GPI antibodies, so perhaps
a genetic and/or racial predisposition for these antibodies [70]. The level of annexin V was markedly reduced on
placental villi in mothers with APS [71]. Furthermore,is present [61]. Guglielmone and Fernandez examined
the relationship between APS isotype and excess risk Rand et al reported in-vitro data showing that tropho-
blasts and endothelial cells exposed to antiphospholipidfrom pregnancy and found that the concurrent presence
of IgG, IgM, and IgA, compared to the presence of a IgG had reduced levels of annexin V as compared to
controls [72]. Furthermore, trophoblasts and endothelialsingle dominant isotype among autoantibodies, seems to
increase the frequency of recurrent spontaneous abor- cells exposed to APA IgG had significantly faster coagu-
lation times [72]. Although this mechanism is a tantaliz-tion [62].
The factors that influence the activity of APS during ingly attractive explanation for thrombosis and fetal
wastage in APS, it might not represent all the factors atpregnancy, as well as the pathogenesis of fetal wastage
in the antiphospholipid antibody syndrome, are only be- play. For example, as I mentioned earlier, low plasma
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concentrations of protein S [66] and mutations in factor through the use of animal models—mostly in mice but
also in rabbits. As I alluded to earlier, the pathogenicityV (factor V Leiden) in patients with APS have been
reported [67]. Evidence in animal models—for example, of APAs is due to their direct thrombogenic role. Evi-
dence supports beta-2-GPI-mediated activation of endo-the pinch-injury model using a femoral vein—suggests
that endothelial damage is a prerequisite for thrombosis thelial cells followed by a series of downstream events
that result in thrombosis. In vivo murine models support[73]. Furthermore, upregulation of adhesion molecules
on endothelial cells and on platelets in APS models also this direct role. For example, Garcia and coworkers have
immunized PL/J mice with beta-2 microglobulin and re-has been reported.
The management of the antiphospholipid antibody ported the development of the antiphospholipid anti-
body syndrome, including adverse pregnancy outcomes,syndrome during lupus has been transformed since the
emergence of evidence that low-dose aspirin and heparin in the beta-2 microglobulin-injected mice [79]. Similarly,
Shoenfeld’s group, in numerous studies, have precipi-markedly reduce the fetal wastage rate. Interfering with
the coagulation cascade rather than suppressing the im- tated APA syndrome by injecting beta-2 microglobulin
into naı¨ve mice [80]. It is interesting that this groupmune response parallels the efficacy of anticoagulation
in treating APS patients who are not pregnant [74]. In- developed monoclonal APL antibodies using the com-
bined method of EBV transformation and somatic celldeed, in a prospective randomized controlled trial, Rai
reported an increase in the rate of live births to mothers hybridization of lymphocytes from patients with APS
[81]. One monoclonal antibody, termed EY2C9, boundgiven a low-dose aspirin and heparin combination from
42% to 71% as compared with births in women given weakly to cardiolipin and other phospholipids, but when
injected into naı¨ve BALB/c mice, EY2C9 produced sus-aspirin alone [75]. These observations correlate with sim-
ilar observations by other investigators [76, 77]. On the tained high titers of antiphospholipid antibodies associ-
ated with prolonged activated partial thromboplastinother hand, prednisone treatment in APA has not been
time. Also, pregnant mice immunized with EY2C9 hadeffective in treating APS during pregnancy [78]. Al-
increased fetal resorption rate (the equivalent of fetalthough immunoadsorbent plasmapheresis or intrave-
loss in the human). Shoenfeld et al hypothesized thatnous immunoglobulin has been used during pregnancy,
EY2C9 dysregulated the idiotypic network and precipi-the data are either sporadic or uncontrolled, and I do
tated the characteristic signs of APS. Other studies usingnot recommend use of these approaches.
anti-CD4 antibodies as well as other approaches have
Conclusions suggested that T-cells are important in immunopatho-
genesis.I have discussed various aspects of the lupus preg-
Dr. Madias: Primary antiphospholipid antibody syn-nancy. Despite more than 40 years of research in this
drome can cause a thrombotic lesion involving glomeruliarea, and following the publication of several hundred
as well as renal arterioles and arteries. Could you pleasepapers, a lack of consensus exists on whether pregnancy
comment on differentiating this lesion in a pregnant pa-exacerbates SLE. Still, we have made many advances in
tient from severe pre-eclampsia and the relatively rareour understanding of the immunologic factors at play in
TTP-HUS?a normal pregnancy and how these adaptations might
Dr. Singh: Remarkably, studies documenting the re-affect autoimmune diseases such as lupus. The impor-
nal pathologic manifestations of APA syndrome havetance of factors that might influence a lupus flare at
been sparse. My colleague, Helmut Rennke, who coinci-conception, including the presence of active disease, in
dentally also described the pathology of the case pre-particular lupus nephritis, have become well appreciated.
sented today, discussed the pathology of the anti-phos-The clinical and pathogenetic aspects of both the neona-
pholipid antibody syndrome in a recent CPC in the Newtal lupus syndrome and the anti-phospholipid syndrome
England Journal of Medicine [82]. In addition, Nochyalso are coming into clearer view. Vigorous efforts are
and coworkers have reviewed the typical histologic le-now focused on elucidating the precise mechanisms that
sions found in the kidney in patients with the APA syn-underlie both the neonatal lupus syndrome and the anti-
drome [83]. They report a vascular nephropathy charac-phospholipid antibody syndrome.
terized by small vessel vaso-occlusive lesions with fibrous
intimal hyperplasia of interlobular arteries, recanalizing
QUESTIONS AND ANSWERS thrombi in arteries, and focal cortical atrophy.
Dr. Nicolaos E. Madias (Executive Academic Dean, Dr. Madias: What is known about other antigens
Tufts University School of Medicine, Boston, Massachu- against which antiphospholipid antibodies are directed?
setts): Is there any information on animal models of the Dr. Singh: As I alluded to in my presentation, anti-
antiphospholipid antibody syndrome? phospholipid antibodies comprise a heterogenous family
Dr. Singh: Yes, a number of studies have explored the of antibodies. The specificity of these antibodies has been
characterized by in-vitro assays. Good evidence suggestsimmunopathogenesis of the antiphospholipid antibodies
Nephrology Forum: Lupus nephritis during pregnancy2250
several candidate protein antigens, including beta-2-gly- Dr. Harrington: Is it simply a shield or does it have
any specific physiological role?coprotein I (beta-2-GPI), prothrombin, and annexin V
[84]. The nature of these interactions is still being investi- Dr. Singh: To the best of my knowledge, the precise
physiologic role for annexins remains unclear.gated. Antiphospholipid antibodies appear to recognize
complexes of phospholipid and phospholipid-binding Dr. Ronald D. Perrone (Division of Nephrology,
New England Medical Center, Boston, Massachusetts):proteins, in particular, phospholipid and prothrombin or
annexin V. The in vitro effect is inhibition of one or You talked about normal pregnancy as a state of dimin-
ished immune response. Does lupus flare after preg-more of the in vitro phospholipid-dependent tests of
coagulation. In vivo, these interactions can activate adhe- nancy? Were you able to determine that from your re-
view of the literature?sion molecules on endothelial cells and downstream of
this placental thrombosis in pregnant women. Of course, Dr. Singh: There is evidence on both sides of the fence
about whether lupus flares in the immediate postpartumthese antibodies also can precipitate one or more of the
protean manifestations of the antiphospholipid antibody period. As I said in my presentation, several older studies
do suggest postpartum flaring, but I found no reports ofsyndrome.
Dr. John T. Harrington (Dean, Tufts University postpartum flaring in prospective controlled studies.
Dr. Madias: Is there evidence that increasing the doseSchool of Medicine): You mentioned that the pathogene-
sis of this syndrome involved the adherence of platelets of prednisone for a short period prior to and after deliv-
ery decreases the frequency of postpartum flares of lupusto activated endothelial cells. Can we block the “sticki-
ness” of the platelets in patients with this syndrome? nephritis?
Dr. Singh: Not to my knowledge. However, a shortDr. Singh: So far, the use of anticoagulation (warfarin
therapy) or aspirin and heparin in pregnant patients is course of steroids prior to and after delivery is quite
safe, and I would not hesitate to use it if I thought thatconsidered established therapy. To my knowledge, no
studies have used anti-ICAM antibodies or, for that mat- the patient were at high risk, for example, in a patient
who already has evidence of serologic activity of lupus,ter, strategies directed at the blockade of the platelet
surface membrane receptors to reduce platelet aggrega- or in someone who has evidence of a low-level flare.
Dr. Andrew J. King (Division of Nephrology, Newtion. As you know, the glycoprotein IIb/IIIa receptor is
in the news because it plays a pivotal role in binding England Medical Center): I’m interested in your con-
struction of the pathogenesis of the increased risk ofcirculating fibrinogen or von Willebrand factor and
thereby crosslinking platelets to increase platelet “sticki- spontaneous abortion in patients with anti-cardiolipin
antibodies. You alluded to an endothelial cell insult fol-ness.” In the cardiac arena, the chimeric monoclonal
antibody fragment abciximab, the peptide inhibitor ep- lowed by expression of adhesion molecules and subse-
quent adhesion by platelets and initiation of thrombosis.tifibatide, and the nonpeptide mimetics tirofiban and
lamifiban have been utilized with some success. I am Is there any evidence that inflammatory cells bind to
adhesion molecules in this circumstance?not aware of trials in patients with the antiphospholipid
antibody syndrome. Dr. Singh: The cellular events that underlie pregnancy
loss in the antiphospholipid antibody syndrome have notDr. Harrington: Tell us about annexin. Why is it
there and what does it do? been completely elucidated. However, I believe that there
is a very interesting study that specifically addresses yourDr. Singh: Annexin V is a member of the annexin
family [84], which comprises anionic phospholipid-binding question. Pierangeli and coworkers recently used a mi-
crocirculation model in mice to demonstrate that anti-proteins previously known by names including placental
anticoagulant protein, vascular anticoagulant, endonexin, phospholipid antibodies directly activate endothelial cells
in vivo [87]. Moreover, endothelial cell activation can belipocortin, calphobindin, calcimedin, calelectrin, and an-
chorin. Annexin V is expressed in a variety of tissues, correlated with in vitro expression of adhesion molecules
(in particular VCAM-1 and E-selectin) on the surface ofalthough its presence in the placenta and vascular endo-
thelium is currently most intriguing. It is a potent antico- human umbilical vein endothelial cell (HUVEC) mono-
layers exposed to antiphospholipid antibodies. Thus,agulant protein because it can displace coagulation fac-
tors from phospholipid surfaces. Rand and colleagues there does appear to be compelling evidence that endo-
thelial cell activation influences hypercoagulability in pa-have investigated its role in pregnancy loss in patients
with the antiphospholipid antibody syndrome because it tients with the antiphospholipid antibody syndrome.
Nevertheless, how antiphospholipid antibodies activateis markedly reduced on placental villi in patients with
this syndrome [85–87]. endothelial cells remains a murky issue. One possibility
is that antiphospholipid antibodies cause endothelial cellDr. Harrington: Is it on the subsurface?
Dr. Singh: Annexin V is expressed on the apical mem- injury, but there are other possibilities.
Dr. King: Is there a breakdown of the immunoprivi-branes of syncytiotrophoblast cells isolated from the pla-
centa. leged status that clearly exists in the placenta?
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Dr. Singh: I’m not aware of any data that show that. distinction between class IIIa and IIIb is of substantial
relevance because the latter is often associated with sub-Dr. King: What do you postulate is the proximate
cause of endothelial cell injury? endothelial immune deposition and behaves more like
a class IV lesion in activity and outcome.Dr. Singh: As I alluded to earlier, some evidence
supports a role for direct injury to the vessel wall and Dr. Steven Ralston (Division of Maternal/Fetal Med-
icine, New England Medical Center): This patient didn’tpresumably to endothelial cells as a prerequisite—for
example, the pinch-injury model using a femoral vein [73]. have a renal biopsy because she was pregnant. Could
you comment on the use of renal biopsy in pregnantDr. Annamaria Kausz (Division of Nephrology, New
England Medical Center): In pregnant women with lupus women?
Dr. Singh: Yes, the patient discussed earlier did notand renal failure, what is the impact of loss of the fetus
on recovery of renal function? That is, can the loss of have a percutaneous renal biopsy because she was preg-
nant. Although we usually shy away from performing apotential immune stimulation be separated from the ef-
fect of the heavy immunosuppression that was instituted renal biopsy in pregnant women, under the appropriate
circumstances a renal biopsy can be performed safely inwhen the pregnancy was lost? Would fetal loss alone
have resulted in renal recovery? a pregnant patient. I have performed several biopsies in
pregnant women with nephritis, and although one mustDr. Singh: Unfortunately, little data are available to
address your question. If one accepts the postulate that perform these biopsies with a great deal of caution, in
every instance the information turned out to be invalu-pregnancy does not exacerbate lupus, then terminating
the pregnancy should not be pursued. On the other hand, able.
Dr. Ralston: What do you do about a lupus patientmany sporadic reports suggest the contrary as well.
Dr. Klemens B. Meyer (Division of Nephrology, New who has mild renal disease with a slightly elevated creati-
nine at the beginning of pregnancy, but who at 24 to 26England Medical Center): You suggested that the wide
range of repeated flare rates, about 20% to 60%, repre- weeks suddenly develops worsening proteinuria and a
slightly increased creatinine?sents variation across different populations. Might not
this variability in small studies just reflect sampling varia- Dr. Singh: Obviously, the differential diagnosis in-
cludes pre-eclampsia, exacerbation of pre-existing renaltion? Perhaps the message is that the rate in the lupus
population is on the order of 40%, the midpoint of that disease, and the de novo presentation of acute glomeru-
lonephritis. After the appropriate workup, a renal biopsyrange. It seems to me that the order of magnitude is
really what’s important. What our patients need to know could be entertained. One usually can make a diagnosis
on clinical and laboratory parameters, however.is that the flare rate is somewhere in this intermediate
range, and that it is not 0.1%, 1%, 99% or 99.9%. I Dr. Dana Miskulin (Renal Fellow, Division of Ne-
phrology, New England Medical Center): Have theresuspect that relatively few people would change their
decisions depending on whether the rate is 20% or 60%. been any studies of ARS patients who developed DVT
during pregnancy that would help guide long-term ther-Dr. Singh: I agree.
Dr. King: Your talk and the literature provide con- apy? Specifically, should these patients be anticoagulated
over the long term?vincing evidence that disease activity at the beginning
of the pregnancy predicts a flare. Can you offer us a Dr. Singh: I would choose low-molecular-weight hep-
arin with aspirin as the preferred treatment.clinical definition of pre-existing disease?
Dr. Singh: A reasonable definition of pre-existing dis- Dr. Mark Sarnak (Division of Nephrology, New En-
gland Medical Center): You described one study usingease is the presence of either extrarenal or renal manifes-
tations of SLE coupled with serologic evidence of activ- subcutaneous heparin, 5000 units twice daily, to prevent
spontaneous abortion. In that study, 13 of 45 pregnanciesity. Of course the more difficult issue is the asymptomatic
patient who has evidence of serologic activity. However, still had poor outcomes. Has anyone used higher doses
of heparin to prevent thrombotic events?as I discussed in my presentation, complement levels can
be difficult to interpret in pregnancy. Dr. Singh: There have been other studies. Low doses
of heparin appear just as effective as higher doses [88].Dr. King: What about the ANA?
Dr. Singh: I believe the ANA to be useful. But al- To specifically answer your question, Kutteh has used
heparin in doses that ranged from 10,000 to 15,000 unitsthough it is sensitive, it has limited specificity. I find
measuring anti-DNA antibody levels and complements subcutaneously to maintain the PTT at 1.2 to 1.5 times
normal [89]. Supplementation with calcium carbonatevery helpful.
Dr. Madias: In patients with quiescent lupus nephritis, also was provided to achieve a total daily intake of 1.5
g/day for all patients. This was to counter the problemsdoes it matter what the underlying pathology is regarding
a renal flare during pregnancy? with bone loss. In this study, the patients appeared to
tolerate the heparin well, and no serious bleeding prob-Dr. Singh: Yes, I believe that whether the patient has
class III versus class IV to be very important. In fact, the lems, episodes of thrombocytopenia, or osteoporotic
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Dr. Madias: How do the effects of lupus nephritis on REFERENCES
the pregnancy compare with those of other glomerulopa- 1. Saito S, Sakai M, Sasaki Y, Tanebe K, Tsuda H, Michimata T:
Quantitative analysis of peripheral blood Th0, Th1, Th2 and thethies?
TH1: Th2 cell ratio during normal human pregnancy and pre-Dr. Singh: Jones and Hayslett examined the effect of
eclampsia. Clin Exp Immunol 117:550–555, 1999
pregnancy on pregnant patients who had a history of 2. Moore M, Sargent IL, Ting A, Redman CW: Maternal cell-medi-
ated immunity in pregnancy: Lymphocyte responses of motherschronic glomerulonephritis or tubulointerstitial nephritis
and their non-pregnant HLA identical sisters to paternal HLA.and mild to moderate renal insufficiency [90]. They noted
Clin Exp Immunol 54:91–94, 1983
a decline in GFR in 20% of patients, an increase in pre- 3. Vanderbeeken Y, Vlieghe MP, Duchateau J, Delespesse G:
Suppressor T-lymphocytes in pregnancy. Am J Reprod Immunolterm delivery and caesarean section, but a high fetal
5:20–24, 1984survival rate—over 90%. I am not aware of an analysis
4. Szekeres-Bartho J, Faust Z, Varga P, Szereday L, Kelemen K:
that has systematically compared the lupus pregnancy The immunological pregnancy protective effect of progesterone
is manifested via controlling cytokine production. Am J Reprodwith other glomerulonephritides.
Immunol 35:348–351, 1996Dr. Rekha Abichandani (Renal Fellow, Division of
5. Szekeres-Bartho JFZ, Varga P: The expression of a progester-
Nephrology, New England Medical Center): My first one-induced immunomodulatory protein in pregnancy lympho-
cytes. Am J Reprod Immunol 34:342–348, 1995question is, which are the most common forms of lupus
6. Reed E, Beer AE, Hutcherson H, King DW, Suciu-Foca N: Thenephritis associated with the antiphospholipid antibody? alloantibody response of pregnant women and its suppression by
My second question is, what do you do with patients soluble HLA antigens and anti-idiotypes antibodies. J Reprod Im-
munol 20:115–128, 1991who have not lost previous pregnancies and have an
7. Suciu-Foca N, Rohowsky-Kochan C, Reed E, Haars R, Bona-isolated antiphospholipid antibody? gura V, King DW, Reemstma K: Idiotypic network regulations
Dr. Singh: Let me first respond to your question of of immune responses to HLA. Fed Proc 44:2483–2487, 1985
8. Nelson J, Hughes KA, Smith AG, Nisperos BB, Branchaudwhether to treat pregnant women considered to be at
AM, Hansen JA: Maternal-fetal disparity in HLA class II alloanti-low risk of the antiphospholipid antibody syndrome, that gens and the pregnancy-induced amelioration of rheumatoid ar-
is, women who have none of the associated signs or thritis. N Engl J Med 329:466–471, 1993
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